钠-葡萄糖共转运蛋白2抑制剂在老年2型糖尿病合并常见心血管疾病中的应用进展
作者:
作者单位:

(1. 中国人民解放军总医院京西医疗区,北京 100144;2. 中国人民解放军总医院第六医学中心心血管病学部,北京 100048)


Advances in application of sodium-glucose co-transporter 2 inhibitor in elderly type 2 diabetes mellitus patients with concomitant common cardiovascular diseases
Author:
Affiliation:

(1. Western Medical Branch, Chinese PLA General Hospital, Beijing 100144, China;2. Senior Department of Cardiology, Sixth Medical Centre, Chinese PLA General Hospital, Beijing 100048, China)

  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献 [37]
  • |
  • 相似文献 [20]
  • | | |
  • 文章评论

    【摘要】老年2型糖尿病(T2DM)患者常有多病共存现象,而合并心血管疾病(CVD)最为常见,是其致残、致死的首要原因。钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)是一种新型降糖药物,其心血管保护作用受到广泛关注,在老年T2DM与CVD共病的治疗上展现出良好的前景。本文就SGLT2i在T2DM合并心力衰竭、高血压、动脉粥样硬化、心肌梗死等常见CVD中的应用研究进展作一综述。

    基金项目:国家自然科学基金(82200366,82370327)

    【Abstract】Elderly patients with type 2 diabetes mellitus (T2DM) often have multiple coexisting diseases, and the complication of cardiovascular diseases (CVD) is the most common, which is the primary cause of disability and death. Sodium-glucose co-transporter protein 2 inhibitor (SGLT2i) is a novel hypoglycemic agent, which has received widespread attention for its cardio-protective effects, and shows good prospects for the treatment of co-morbidities of T2DM and CVD in the elderly. In this article, we reviewed the progress of SGLT2i in T2DM combined with heart failure, hypertension, atherosclerosis, myocardial infarction and other common CVD.

    This work was supported by the National Natural Science Foundation of China (82200366, 82370327).

    参考文献
    [1] Yao SS, Cao GY, Han L, et al.Prevalence and patterns of multimorbidity in a nationally representative sample of older Chinese:results from the China Health and Retirement Longitudinal Study[J].J Gerontol A Biol Sci Med Sci, 2020,75(10):1974-1980.DOI:10.1093/gerona/glz185.
    [2] 吕晓燕, 李蓉, 李雨欣, 等.共病研究热点及趋势分析[J].中国医学科学院学报, 2022,44(4):643-653.DOI:10.3881/j.issn.1000-503X.14530.
    [3] Heikkala E, Mikkola I, Jokelainen J, et al.Multimorbidity and achievement of treatment goals among patients with type 2 diabetes:a primary care, real-world study[J].BMC Health Serv Res, 2021,21(1):964.DOI:10.1186/s12913-021-06989-x.
    [4] Mosenzon O, Alguwaihes A, Leon JLA, et al.CAPTURE:a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries[J].Cardiovasc Diabetol, 2021,20(1):154.DOI:10.1186/s12933-021-01344-0.
    [5] Ma CX, Ma XN, Guan CH, et al.Cardiovascular disease in type 2 diabetes mellitus:progress toward personalized management[J].Cardiovasc Diabetol, 2022,21(1):74.DOI:10.1186/s12933-022-01516-6.
    [6] Kario K, Okada K, Kato M, et al.Twenty-four-hour blood pressure-lowering effect of a sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension:results from the randomized, placebo-controlled SACRA study[J].Circulation, 2019,139(18):2089-2097.DOI:10.1161/CIRCULATIONAHA.118.037076.
    [7] Neal B, Perkovic V, Matthews DR, et al.Canagliflozin and cardio-vascular and renal events in type 2 diabetes[J].N Engl J Med, 2017,377(7):644-657.DOI: 10.1056/NEJMoa1611925.
    [8] Kaplinsky E.DAPA-HF trial:dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure[J].Drugs Context, 2020,9:2019-11-3.DOI:10.7573/dic.2019-11-3.
    [9] Inzucchi SE, Claggett BL, Vaduganathan M, et al.Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER):a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial[J].Lancet Diabetes Endocrinol, 2022,10(12):869-881.DOI:10.1016/S2213-8587(22)00308-4.
    [10] Ushakov A, Ivanchenko V, Gagarina A.Heart failure and type 2 diabetes mellitus:neurohumoral, histological and molecular interconnections[J].Curr Cardiol Rev, 2023,19(2):e170622206132.DOI:10.2174/1573403X18666220617121144.
    [11] Seferovi'c PM, Petrie MC, Filippatos GS, et al.Type 2 diabetes mellitus and heart failure:a position statement from the Heart Failure Association of the European Society of Cardiology[J].Eur J Heart Fail, 2018,20(5):853-872.DOI:10.1002/ejhf.1170.
    [12] Bhatt DL, Szarek M, Steg PG, et al.Sotagliflozin in patients with diabetes and recent worsening heart failure[J].N Engl J Med, 2021,384(2):117-128.DOI:10.1056/NEJMoa2030183.
    [13] Kosiborod MN, Angermann CE, Collins SP, et al.Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure:results from the EMPULSE trial[J].Circulation, 2022,146(4):279-288.DOI:10.1161/CIRCULATIONAHA.122.059725.
    [14] 中国心力衰竭中心联盟专家委员会, 廖玉华, 杨杰孚, 等.心力衰竭SGLT2抑制剂临床应用的中国专家共识[J].临床心血管病杂志, 2022,38(8):599-605.DOI:10.13201/j.issn.1001-1439.2022.08.001.
    [15] Writing Committee Members, Virani SS, Newby LK, et al.2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease:a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines[J].J Am Coll Cardiol, 2023,82(9):833-955.DOI:10.1016/j.jacc.2023.04.003.
    [16] Velliou M, Polyzogopoulou E, Ventoulis I, et al.Clinical pharmacology of SGLT-2 inhibitors in heart failure[J].Expert Rev Clin Pharmacol, 2023,16(2):149-160.DOI:10.1080/17512433.2023.2173574.
    [17] Tong PC, Chan SC, Chan WB, et al.Consensus statements from the diabetologists & endocrinologists alliance for the management of people with hypertension and type 2 diabetes mellitus[J].J Clin Med, 2023,12(10):3403.DOI:10.3390/jcm12103403.
    [18]Sjöström CD, Johansson P, Ptaszynska A, et al.Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes[J].Diab Vasc Dis Res, 2015,12(5):352-358.DOI:10.1177/1479164115585298.
    [19] Sanidas EA, Papadopoulos DP, Hatziagelaki E, et al.Sodium glucose cotransporD-REAL 2 study[J].J Am Coll Cardiol, 2018,71(23):2628-2639.DOI:10.1016/j.jacc.2018.03.009.
    [36] American Diabetes Association Professional Practice Committee.2.Classification and diagnosis of diabetes:standards of medical care in diabetes-2022[J].Diabetes Care, 2022,45(Suppl 1):S17-S38.DOI:10.2337/dc22-S002.
    crinology and Metabolism Branch of Chinese Geriatric Health Care Society, et al.Clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China (2022 edition)[J].Chin J Intern Med, 2022,61(1):12-50.DOI:10.3760/cma.j.cn112138-20211027-00751.
    [21] Watanabe D, Gando Y, Murakami H, et al.Longitudinal trajectory of vascular age indices and cardiovascular risk factors:a repeated-measures analysis[J].Sci Rep, 2023,13(1):5401.DOI:10.1038/s41598-023-32443-5.
    [22] Szekeres Z, Toth K, Szabados E.The effects of SGLT2 inhibitors on lipid metabolism[J].Metabolites, 2021,11(2):87.DOI:10.3390/metabo11020087.
    [23] Han JH, Oh TJ, Lee G, et al.The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE-/- mice fed a western diet[J].Diabetologia, 2017,60(2):364-376.DOI:10.1007/s00125-016-4158-2.
    [24] Chen YC, Jandeleit-Dahm K, Peter K.Sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin stabilizes diabetes-induced athero-sclerotic plaque instability[J].J Am Heart Assoc, 2022,11(1):e022761.DOI:10.1161/JAHA.121.022761.
    [25] Lee HF, Chen SW, Liu JR, et al.Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor[J].Cardiovasc Diabetol, 2020,19(1):160.DOI:10.1186/s12933-020-01118-0.
    [26] Miyashita S, Kuno T, Takagi H, et al.Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors:a meta-analysis of five randomized controlled trials[J].Diabetes Res Clin Pract, 2020,163:108136.DOI:10.1016/j.diabres.2020.108136.
    [27] Pahud de Mortanges A, Salvador D Jr, Laimer M, et al.The role of SGLT2 inhibitors in atherosclerosis:a narrative mini-review[J].Front Pharmacol, 2021,12:751214.DOI:10.3389/fphar.2021.751214.
    [28] Cui J, Liu Y, Li Y, et al.Type 2 diabetes and myocardial infarction:recent clinical evidence and perspective[J].Front Cardiovasc Med, 2021,8:644189.DOI:10.3389/fcvm.2021.644189.
    [29] Johansson S, Rosengren A, Young K, et al.Mortality and morbidity trends after the first year in survivors of acute myocardial infarction:a systematic review[J].BMC Cardiovasc Disord, 2017,17(1):53.DOI:10.1186/s12872-017-0482-9.
    [30] Jiang K, Xu Y, Wang D, et al.Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis[J].Protein Cell, 2022,13(5):336-359.DOI:10.1007/s13238-020-00809-4.
    [31] Paolisso P, Bergamaschi L, Santulli G, et al.Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors:a multicenter international registry[J].Cardiovasc Diabetol, 2022,21(1):77.DOI:10.1186/s12933-022-01506-8.
    [32] Furtado RHM, Bonaca MP, Raz I, et al.Dapagliflozin and cardio-vascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction[J].Circulation, 2019,139(22):2516-2527.DOI:10.1161/CIRCULATIONAHA.119.039996.
    [33] Cherney DZ, Udell JA.Use of sodium glucose cotransporter 2 inhibitors in the hands of cardiologists:with great power comes great responsibility[J].Circulation, 2016,134(24):1915-1917.DOI:10.1161/CIRCULATIONAHA.116.024764.
    [34] Udell JA, Jones WS, Petrie MC, et al.Sodium glucose cotransporter-2 inhibition for acute myocardial infarction:JACC review topic of the week[J].J Am Coll Cardiol, 2022,79(20):2058-2068.DOI:10.1016/j.jacc.2022.03.353.
    [35] Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study[J]. J Am Coll Cardiol, 2018, 71(23): 2628-2639.DOI: 10.1016/j.jacc.2018.03.009.
    [36] American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45(Suppl 1): S17-S38.DOI: 10.2337/dc22-S002.
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

张辉,李泱,刘传斌.钠-葡萄糖共转运蛋白2抑制剂在老年2型糖尿病合并常见心血管疾病中的应用进展[J].中华老年多器官疾病杂志,2024,23(8):624-627

复制
分享
文章指标
  • 点击次数:58
  • 下载次数: 4157
  • HTML阅读次数: 0
  • 引用次数: 0
历史
  • 收稿日期:2023-11-07
  • 在线发布日期: 2024-08-23
文章二维码